0000899243-23-006581.txt : 20230301
0000899243-23-006581.hdr.sgml : 20230301
20230301161427
ACCESSION NUMBER: 0000899243-23-006581
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230227
FILED AS OF DATE: 20230301
DATE AS OF CHANGE: 20230301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dolmetsch Ricardo
CENTRAL INDEX KEY: 0001825206
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36294
FILM NUMBER: 23693672
MAIL ADDRESS:
STREET 1: 113 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: uniQure N.V.
CENTRAL INDEX KEY: 0001590560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
BUSINESS PHONE: 1-339-970-7000
MAIL ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
FORMER COMPANY:
FORMER CONFORMED NAME: uniQure B.V.
DATE OF NAME CHANGE: 20131030
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-27
0
0001590560
uniQure N.V.
QURE
0001825206
Dolmetsch Ricardo
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
AMSTERDAM
P7
11058BP
NETHERLANDS
0
1
0
0
President, R&D
Ordinary Shares
2023-02-27
4
S
0
6944
19.58
D
170082
D
As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
The price reported in Column 4 is a weighted average price. 6,824 of the shares were sold in multiple transactions at prices ranging from $19.21 to $19.81, 63 of the shares were sold at $20.86 and 57 of the shares were sold at $20.87. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Christian Klemt, Attorney-in-Fact
2023-03-01